Global Alzheimer’s Platform Foundation - Customer Case Study

One of several collaborations with GAP, Linus Health was a digital cognitive assessment partner in the groundbreaking Bio-Hermes study, GAP’s first-ever blood-based and digital biomarker study. Concluding in late 2022, Bio-Hermes focused on advancing timely Alzheimer’s disease (AD) detection by comparing dozens of blood tests, digital cognitive tests, retinal exams, and speech analysis to traditional methods of assessing cognition and AD pathology. The study enrolled over 1,000 participants, including those with no reported cognitive concerns, some with mild cognitive impairment, and some with early stage AD. Bio-Hermes had participant diversity as a key endpoint and exceeded its goal with 24% of volunteers coming from traditionally underrepresented communities.